The initial public offering (IPO) market is set to maintain the previous week's momentum, with 10 traditional IPOs set to raise more than $2 billion in their debuts.
Lyell Immunopharma, Inc. (NASDAQ: LYEL) plans to raise nearly $518 million from 25 million shares priced in the range of $16 to $18 each. The biotech company's pipeline contains preclinical candidates using proprietary genetic and epigenetic reprogramming to develop T cell therapies to treat solid tumors. Lyell plans to submit four Investigative New Drug forms to the U.S. Food and Drug Administrations by the end of next year.
WalkMe Ltd. (NASDAQ: WKME) plans to raise more than $340 million from 9.25 million shares priced in the range of $29 to $32 each. The Israel-based customer engagement and business insight platform had about 2,000 customers as of March 31, including 155 of the Fortune 500.
Convey Holding Parent, Inc. (NYSE: CNVY) plans to raise more than $245 million from over 13.3 million shares priced between $14 to $16 each. The medicare solutions provider enters partnerships with healthcare companies with the intent to improve government-sponsored health plans.
AiHuiShou International Co., Ltd. (NYSE: RERE) plans to raise $227 million from 16.2 million shares priced in the range of $13 to $15 each. The Shanghai-based company operates Paijitang Marketplace, a leading Chinese business-to-business marketplace for electronic products and services, and Paipai Marketplace, a retail ecommerce marketplace for pre-owned electronics.
ATAI Life Sciences N.V. (NASDAQ: ATAI) plans to raise more than $214 million from offering 14.29 million shares priced between $15 to $17 each. The German psychedelices company looks to innovate mental health treatments, with its pipeline containing 10 development programs and six enabling technologies using psychedelics.
Angel Oak Mortgage, Inc. (NYSE: AOMR) plans to raise more than $194 million from 8.05 million shares priced in the range of $20 to $21 each. The mortgage REIT's portfolio is mostly comprised of first lien loans that are sources from its proprietary mortgage lending platform.
AMTD Digital Inc. (NYSE: HKD) plans to raise more than $150 million from 2.4 million shares priced between $6.80 to $8.20 each. The digital financial services provider operates in Asia, and primarily generates revenue from fees and commissions.
Molecular Partners AG (NASDAQ: MOLN) plans to raise nearly $94 million from 3 million shares priced at $27.14 each. The Swiss biotech uses its proprietary molecular platform to create product candidates, and is currently in development partnerships with Novartis (NYSE: NVS), Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).
Unicycle Therapeutics, Inc. (NASDAQ: UNCY) plans to raise nearly $32 million from more than 2.6 million shares priced between $8.50 to $10.50 each. The biotech is focused on the treatment of kidney diseases, and has begun conducting preclinical trials for one of its lead candidates this year.
Acurx Pharmaceuticals, LLC (NASDAQ: ACXP) plans to raise over $20 million from 2.5 million shares priced in the range of $5 to $7 each. The clinical-stage biopharmaceutical company is developing a new class of antibiotics for bacterial infections.